The Food and Drug Administration has rescinded a partial hold on OncoMed Pharmaceuticals’ patient enrollments for three cancer-drug trials, the company said Thursday. The drug, vantictumab, is in Phase 1 clinical trials.
Reuters reported OncoMed’s stock jumped as much as 9% in early trading and noted that patient enrollment could pick up again following approval of revised trial protocol. Studies examined lung, breast, and pancreatic cancer patients.
According to FierceBiotech, Bayer paid $40 million upfront as part of a partnership begun in 2010 worth $430 million for “the right to buy in up to five drug candidates,” pending study results.